Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal Infections

Clinical Infectious Diseases

Volumn 37, Issue 8, 2003, Pages 997-1005

  Solomkin, Joseph S ^a   Mazuski, John E ^b   Baron, Ellen J ^c   Sawyer, Robert G ^d   Nathens, Avery B ^e   DiPiro, Joseph T ^f,g   Buchman, Timothy ^b   Dellinger, E Patchen ^e   Jernigan, John ^h   Gorbach, Sherwood ⁱ   Chow, Anthony W ^k   Bartlett, John ^j  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF GEORGIA   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CASPOFUNGIN; CEFAZOLIN; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; MONOBACTAM DERIVATIVE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TIMENTIN; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ANTIMICROBIAL THERAPY; BACTEROIDES FRAGILIS; DIGESTIVE SYSTEM PERFORATION; DRUG SENSITIVITY; DRUG TOXICITY; GRAM NEGATIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; MICROBIOLOGY; NONHUMAN; PERITONITIS; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ABDOMINAL ABSCESS; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FORECASTING; HUMANS; PERITONITIS; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 0142187282     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378702     Document Type: Review

References (71)

1. Berne TV, Yellin AW, Appleman MD, Heseltine PN. Antibiotic management of surgically treated gangrenous or perforated appendicitis: comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone. Am J Surg 1982; 144:8-13.
2. Yellin AE, Heseltine PN, Berne TV, et al. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985; 161: 303-7.
3. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg 1990; 212:581-91.
4. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214:543-9.
5. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996; 15: 913-21.
6. Wilton P, Smith R, Coast J, Millar M. Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness. J Health Serv Res Policy 2002; 7:111-7.
7. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584-99.
8. Kish MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32:851-4.
9. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surgical Infections 2002; 3:161-74.
10. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Surg Infect 2002; 3: 175-234.
11. Bohnen JM, Solomkin JS, Dellinger EP, Bjornson HS, Page CP. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992; 127:83-9.
12. Boey J, Wong J, Ong GB. Bacteria and septic complications in patients with perforated duodenal ulcers. Am J Surg 1982; 143:635-9.
13. Fong IW. Septic complications of perforated peptic ulcer. Can J Surg 1983; 26:370-2.
14. Westphal JF, Brogard JM. Biliary tract infections: a guide to drug treatment. Drugs 1999; 57:81-91.
15. Rau B, Pralle U, Mayer JM, Beger HG. Role of ultrasonographically guided fine-needle aspiration cytology in the diagnosis of infected pancreatic necrosis. Br J Surg 1998; 85:179-84.
16. Kramer KM, Levy H. Prophylactic antibiotics for severe acute pancreatitis: the beginning of an era. Pharmacotherapy 1999; 19:592-602.
17. Kacew S, Bergeron MG. Pathogenic factors in aminoglycoside-induced nephrotoxicity. Toxicol Lett 1990; 51:241-59.
18. Walker AP, Nichols RL, Wilson RF, et al. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 1993; 217:115-21.
19. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/ oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000; 232:254-62.
20. Ohlin B, Cederberg A, Forssell H, Solhaug JH, Tveit E. Piperacillin/ tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg 1999; 165:875-84.
21. Eklund AE, Nord CE. A randomized multicenter trial of piperacillin/ tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. J Antimicrob Chemother 1993; 31(Suppl A):79-85.
22. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-72.
23. Allo MD, Bennion RS, Kathir K, et al. Ticarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitis. Am Surg 1999; 65:99-104.
24. Dougherty SH, Sirinek KR, Schauer PR, et al. Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg 1995; 61:297-303.
25. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237:235-45.
26. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996; 223:303-15.
27. Solomkin JS, Wilson SE, Christou NV, et al. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg 2001; 233:79-87.
28. Angeras MH, Darle N, Hamnstrom K, et al. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Scand J Infect Dis 1996; 28:513-8.
29. Barie PS, Vogel SB, Dellinger EP, et al. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-Abdominal Infection Study Group. Arch Surg 1997; 132:1294-302.
30. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995; 35:139-48.
31. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992; 36:2766-73.
32. Christou NV, Turgeon P, Wassef R, Rotstein O, Bohnen J, Potvin M. Management of intra-abdominal infections: the case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-Abdominal Infection Study Group. Arch Surg 1996; 131:1193-201.
33. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/ cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother 1996; 38:523-37.
34. Donahue PE, Smith DL, Yellin AE, Mintz SJ, Bur F, Luke DR. Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Trovafloxacin Surgical Group. Am J Surg 1998; 176:53S-61S.
35. Poenaru D, De Santis M, Christou NV. Imipenem versus tobramycin - antianaerobe antibiotic therapy in intra-abdominal infections. Can J Surg 1990; 33:415-22.
36. Basoli A, Meli EZ, Mazzocchi P, Speranza V. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Scand J Infect Dis 1997; 29:503-8.
37. Berne TV, Yellin AE, Appleman MD, Heseltine PN, Gill MA. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. J Am Coll Surg 1996; 182:403-7.
38. Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995; 21:544-50.
39. Geroulanos SJ. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group. J Antimicrob Chemother 1995; 36(Suppl A):191-205.
40. Huizinga WK, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995; 36(Suppl A):179-89.
41. Wilson SE, Boswick JA Jr, Duma RJ, et al. Cephalosporin therapy in intraabdominal infections: a multicenter randomized, comparative study of cefotetan, moxalactam, and cefoxitin. Am J Surg 1988; 155: 61-6.
42. Luke M, Iversen J, Sondergaard J, et al. Ceftriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 1991; 157:397-401.
43. Angeras MH, Darle N, Hamnstrom K, et al. A comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infections. Scand J Infect Dis 1996; 28:513-8.
44. Mehtar S, Dewar EP, Leaper DJ, Taylor EW. A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections. J Antimicrob Chemother 1997; 39:631-8.
45. Solomkin JS, Hemsell DL, Sweet R, Tally F, Bartlett J. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15(Suppl 1):S33-42.
46. McGowan JE Jr, Gerding DN. Does antibiotic restriction prevent resistance? New Horiz 1996; 4:370-6.
47. Bieluch VM, Cuchural GJ, Snydman DR, Gorbach SL, Tally FP. Clinical importance of cefoxitin-resistant Bacteroides fragilis isolates. Diagn Microbiol Infect Dis 1987; 7:119-26.
48. Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000; 30:870-6.
49. Snydman DR, Cuchural GJ Jr, McDermott L, Gill M. Correlation of various in vitro testing methods with clinical outcomes in patients with Bacteroides fragilis group infections treated with cefoxitin: a retrospective analysis. Antimicrob Agents Chemother 1992; 36:540-4.
50. Shapiro ME, Onderdonk AB, Kasper DL, Finberg RW. Cellular immunity to Bacteroides fragilis capsular polysaccharide. J Exp Med 1982; 155:1188-97.
51. Christou NV, Barie PS, Dellinger EP, Waymack JP, Stone HH. Surgical Infection Society intra-abdominal infection study: prospective evaluation of management techniques and outcome. Arch Surg 1993; 128: 193-8.
52. Dellinger EP, Wertz MJ, Meakins JL, et al. Surgical infection stratification system for intra-abdominal infection: multicenter trial. Arch Surg 1985; 120:21-9.
53. Ohmann C, Wittmann DH, Wacha H. Prospective evaluation of prognostic scoring systems in peritonitis. Peritonitis Study Group. Eur J Surg 1993; 159:267-74.
54. Wacha H, Hau T, Dittmer R, Ohmann C. Risk factors associated with intraabdominal infections: a prospective multicenter study. Peritonitis Study Group. Langenbecks Arch Surg 1999; 384:24-32.
55. Lennard ES, Dellinger EP, Wertz MJ, Minshew BH. Implications of leukocytosis and fever at conclusion of antibiotic therapy for intra-abdominal sepsis. Ann Surg 1982; 195:19-24.
56. Kokoska ER, Silen ML, Tracy TF Jr, et al. The impact of intraoperative culture on treatment and outcome in children with perforated appendicitis. J Pediatr Surg 1999; 34:749-53.
57. Bilik R, Burnweit C, Shandling B. Is abdominal cavity culture of any value in appendicitis? Am J Surg 1998; 175:267-70.
58. Taylor E, Dev V, Shah D, Festekjian J, Gaw F. Complicated appendicitis: is there a minimum intravenous antibiotic requirement? A prospective randomized trial. Am Surg 2000; 66:887-90.
59. Lennard ES, Minshew BH, Dellinger EP, Wertz M. Leukocytosis at termination of antibiotic therapy: its importance for intra-abdominal sepsis. Arch Surg 1980; 115:918-21.
60. Aldridge KE, O'Brien M. In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall susceptibility data. J Clin Microbiol 2002; 40:4349-52.
61. Cuchural GJ Jr, Tally FP, Jacobus NV, et al. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother 1988; 32:717-22.
62. Snydman DR, McDermott L, Cuchural GJ Jr, et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clin Infect Dis 1996; 23(Suppl 1):S54-65.
63. Snydman DR, Jacobus NV, McDermott LA, et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother 1999; 43:2417-22.
64. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin Infect Dis 2002; 35:5126-34.
65. NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. 5th ed. NCCLS document M11-A5. Wayne, PA: NCCLS, 2001.
66. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996; 23:486-94.
67. Peoples JB. Candida and perforated peptic ulcers. Surgery 1986; 100: 758-64.
68. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P. Clinical significance of Candida isolated from peritoneum in surgical patients. Lancet 1989; 2:1437-40.
69. Solomkin JS, Flohr AB, Quie PG, Simmons RL. The role of Candida in intraperitoneal infections. Surgery 1980; 88:524-30.
70. Sirinek KR, Levine BA. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet 1991; 172(Suppl):30-5.
71. Polk HC Jr, Fink MP, Laverdiere M, et al. Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group. Am Surg 1993; 59:598-605.